Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

Autor: Shapiro, Jeremy D., Thavaneswaran, Subotheni, Underhill, Craig R., Robledo, Kristy P., Karapetis, Christos S., Day, Fiona L., Nott, Louise M., Jefford, Michael, Chantrill, Lorraine A., Pavlakis, Nick, Tebbutt, Niall C., Price, Timothy. J., Khasraw, Mustafa, Van Hazel, Guy A., Waring, Paul M., Tejpar, Sabine, Simes, John, Gebski, Val J., Desai, Jayesh, Segelov, Eva
Zdroj: In Clinical Colorectal Cancer December 2018 17(4):313-319
Databáze: ScienceDirect
Externí odkaz: